All Stories

  1. Troponin Thresholds for Risk Stratification of Chest Pain Patients Presenting to the Emergency Department: Alternatives to the 99th Percentile
  2. ICare-FASTER (Improving Care by Faster Risk Stratification Through Use of High-Sensitivity Point-of-Care Troponin in Patients Presenting With Possible Acute Coronary Syndrome in the Emergency Department): A Stepped-Wedge Cluster-Randomized Trial
  3. Protocol for an individual patient data meta-analysis for the assessment of risk factors affecting the development and outcome of functional and structural acute kidney injury after cardiac surgery: the METARIS CS-AKI study
  4. Analytical Verification of a Point-of-Care High-Sensitivity Troponin I Assay
  5. Prognostic performance of plasma and urinary biomarkers of kidney injury and function after out-of-hospital cardiac arrest
  6. External Validation of a Universal Laboratory Pathway for Early Risk Stratification of Myocardial Infarction in the Emergency Setting
  7. Reimagining the vividness of visual imagery questionnaire as a single item screener for aphantasia
  8. Difference of Admission Neutrophil Gelatinase-Associated Lipocalin Concentration Between Patients Developing and Not Developing Acute Kidney Injury or Need for Acute Dialysis: An Ancillary Individual-Study Data Meta-Analysis (INDICATE–AKI)
  9. Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomized trial
  10. Considerations and pragmatic strategies for implementation of point of care testing for high sensitivity cardiac troponin into the acute care setting
  11. Analytical Verification of a Point-of-Care High-Sensitivity Troponin I Assay
  12. Point‐of‐Care High‐Sensitivity Troponin Use in an ESC ‐Type Pathway for Assessment of Possible Acute Myocardial Infarction in the Emergency Department
  13. Mild and moderate traumatic brain injury: Screening, documentation, and referral to concussion services
  14. Soluble urokinase plasminogen activator receptor (suPAR) for risk stratification from undifferentiated acute chest pain through to convalescence after acute coronary syndromes
  15. Potential impact of a point-of-care high-sensitivity cardiac troponin assay on emergency department length of stay and patient disposition: findings from a cardiac emergency department
  16. Common Change Criteria for High-Sensitivity Cardiac Troponin for Serial Measurements Greater Than 2 Hours Apart
  17. Improving Emergency Department Prescribing of Anticoagulation for Atrial Fibrillation Through an Iterative Quality Improvement Process
  18. Giant Outer Transiting Exoplanet Mass (GOT ‘EM) Survey. VI. Confirmation of a Long-period Giant Planet Discovered with a Single TESS Transit
  19. Improving Care with the First measurement of high-sensitivity troponin T (ICare-FirsT) to enable early rule out and reduce length of stay: a diagnostic and observational study
  20. Response to: Clinical Reflections on the Impact of High‐Sensitivity Troponin I Assay Changes on Emergency Department Diagnosis and Disposition
  21. Atrial fibrillation patients presenting to an emergency department successfully managed with a next‐day community follow‐up pathway: A before‐and‐after cohort study
  22. Evaluation of a virtual emergency care service to avoid unnecessary emergency department presentations and provide specialist‐led definitive care
  23. Photometric calibration of the Unistellar telescopes to the Johnson-Cousins System
  24. Potential length of stay reductions from emergency department use of a point‐of‐care high‐sensitivity cardiac troponin assay: Pilot findings from Australia's first cardiac emergency department
  25. Effect of change of high‐sensitivity troponin I assay on emergency department diagnosis and disposition of patients with possible acute coronary syndrome
  26. Insulin-like growth factor binding protein-3 (IGFBP-3): a biomarker of coronary artery disease induced myocardial ischaemia
  27. Evidence-based medicine and the cardiac troponin 99th percentile for the diagnosis of acute myocardial infarction
  28. Clinical derivation and data simulated validation of rule-out and rule-in algorithms for the Siemens Atellica IM high-sensitivity cardiac troponin I assay
  29. Emergency department use of a high-sensitivity point-of-care troponin assay reduces length of stay: an implementation study preliminary report
  30. Analytical verification of the Atellica VTLi point of care high sensitivity troponin I assay
  31. Prognostic performance of soluble urokinase plasminogen activator receptor for heart failure or mortality in Western and Asian patients with acute breathlessness
  32. Protocol for Improving Care by FAster risk-STratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the EmeRgency department (ICare-FASTER): a stepped-wedge cluster randomised...
  33. Determination of Clinically Acceptable Analytical Variation of Cardiac Troponin at Decision Thresholds
  34. Convalescent Growth Differentiation Factor-15 and Long-Term Outcomes after an Acute Coronary Syndrome
  35. Derivation and Validation of Thresholds Using Synthetic Data Methods for Single-Test Screening of Emergency Department Patients with Possible Acute Myocardial Infarction Using a Point-of-Care Troponin Assay
  36. Determination of a whole-blood single-test low-risk threshold for a point-of-care high-sensitivity troponin assay
  37. Troponin thresholds for myocardial infarction risk stratification
  38. Comparison of three creatinine-based equations to predict adverse outcome in a cardiovascular high-risk cohort: an investigation using the SPRINT research materials
  39. Assay of macrotroponin I not complexed with troponin T: effect on the performance of troponin T to predict myocardial infarction
  40. Twenty-six years of machine learning for ECG: and we are not there yet
  41. Machine learning for decision-making in cardiology: a narrative review to aid navigating the new landscape
  42. Post Hoc Analyses of a Randomized Controlled Trial for the Effect of Pharmacist Deprescribing Intervention on the Anticholinergic Burden in Frail Community-Dwelling Older Adults
  43. Analytic Result Variation for High-Sensitivity Cardiac Troponin: Interpretation and Consequences
  44. Ruling out acute myocardial infarction based on a single high-sensitivity troponin measurement in the emergency department: a clinical practice review
  45. Chronic health conditions and mortality among older adults with complex care needs in Aotearoa New Zealand
  46. Implementation of an integrated emergency department acute atrial fibrillation pathway safely reduces cardioversions and hospitalisations: A comparative pre–post study
  47. Personalized diagnosis in suspected myocardial infarction
  48. Factors predictive of spontaneous reversion to sinus rhythm: Findings from an integrated acute atrial fibrillation pathway
  49. Machine learning for diagnosis of myocardial infarction using cardiac troponin concentrations
  50. An integrated signature of extracellular matrix proteins and a diastolic function imaging parameter predicts post-MI long-term outcomes
  51. Comparison of SPEED, S-Trap, and In-Solution-Based Sample Preparation Methods for Mass Spectrometry in Kidney Tissue and Plasma
  52. Light curves and colours of the ejecta from Dimorphos after the DART impact
  53. Deprescribing Anticholinergic and Sedative Drugs to Reduce Polypharmacy in Frail Older Adults Living in the Community: A Randomized Controlled Trial
  54. The Unistellar Exoplanet Campaign: Citizen Science Results and Inherent Education Opportunities
  55. The cost savings of the rural accelerated chest pain pathway for low-risk chest pain in rural general practice: a cost minimisation analysis
  56. Evaluation of the added value of Brain Natriuretic Peptide to a validated mortality risk-prediction model in older people using a standardised international clinical assessment tool
  57. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease
  58. Diagnostic and prognostic performance of the ratio between high-sensitivity cardiac troponin I and troponin T in patients with chest pain
  59. Citizen science astronomy with a network of small telescopes: the launch and deployment of JWST
  60. Validation of the myocardial-ischaemic-injury-index machine learning algorithm to guide the diagnosis of myocardial infarction in a heterogenous population: a prespecified exploratory analysis
  61. A prospective multi-centre study assessing the safety and effectiveness following the implementation of an accelerated chest pain pathway using point-of-care troponin for use in New Zealand rural hospital and primary care settings
  62. Implementation and evaluation of a rural general practice assessment pathway for possible cardiac chest pain using point-of-care troponin testing: a pilot study
  63. Identifying Candidate Protein Markers of Acute Kidney Injury in Acute Decompensated Heart Failure
  64. Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction
  65. Harnessing the Power of “Omics”: Discovering Novel microRNA and Protein Biomarkers of Acute Kidney Injury in Acute Heart Failure
  66. The ROC Diagonal is Not Layperson’s Chance: A New Baseline Shows the Useful Area
  67. Sensitivity of modern multislice CT for subarachnoid haemorrhage at incremental timepoints after headache onset: a 10-year analysis
  68. Deprescribing to reduce polypharmacy: study protocol for a randomised controlled trial assessing deprescribing of anticholinergic and sedative drugs in a cohort of frail older people living in the community
  69. Machine learning with D-dimer in the risk stratification for pulmonary embolism: a derivation and internal validation study
  70. Emergency department frequent attenders: big data insights for a big and complex problem
  71. Next-Day Troponin Tests in Real-World Implementation of Baseline Troponin Rule-Out of Myocardial Infarction Demonstrates Minimal Delayed Troponin Rises
  72. Identifying Candidate Protein Markers of Acute Kidney Injury in Acute Decompensated Heart Failure
  73. Sex-Specific Kinetics of High-Sensitivity Cardiac Troponin I and T following Symptom Onset and Early Presentation in Non-ST-Segment Elevation Myocardial Infarction
  74. Development and validation of multivariable mortality risk-prediction models in older people undergoing an interRAI home-care assessment (RiskOP)
  75. Validation of a machine learned model to predict the diagnosis of myocardial infarction
  76. Predictors of Residential Care Admission in Community-Dwelling Older People With Dementia
  77. Frailty of Māori, Pasifika, and Non-Māori/Non-Pasifika Older People in New Zealand: A National Population Study of Older People Referred for Home Care Services
  78. Prioritizing Candidates of Post–Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics
  79. Effect of Capacity to Undertake Instrumental Activities of Daily Living on Entry to Aged Residential Care in Older People With Heart Failure
  80. Early kinetic profiles of troponin I and T measured by high-sensitivity assays in patients with myocardial infarction
  81. Study protocol for an observational study to evaluate an accelerated chest pain pathway using point-of-care troponin in New Zealand rural and primary care populations
  82. <p>Gait Speed at Discharge and Risk for Readmission or Death: A Prospective Study of an Emergency Ward Population</p>
  83. Undetectable high-sensitivity troponin in combination with clinical assessment for risk stratification of patients with chest pain and normal troponin at hospital arrival
  84. Emerging microRNA biomarkers for acute kidney injury in acute decompensated heart failure
  85. Do It Yourself Automated Insulin Delivery: A Leading Example of the Democratization of Medicine
  86. P2674Rapid rule-out of myocardial infarction with a novel high precision point-of-care troponin assay appears safe and effective
  87. Application of High-Sensitivity Troponin in Suspected Myocardial Infarction
  88. Diagnosis of acute myocardial infarction in the presence of left bundle branch block
  89. The Need to Improve Derivation and Description of Algorithms to Rule-Out Patients With Possible Myocardial Infarction
  90. Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction—Reply
  91. Heart failure and the risk of acute kidney injury in relation to ejection fraction in patients undergoing coronary artery bypass grafting
  92. Validity of a Novel Point-of-Care Troponin Assay for Single-Test Rule-Out of Acute Myocardial Infarction
  93. Combining Novel Renal Injury Markers with Delta Serum Creatinine Early after Cardiac Surgery and Risk-Stratification for Serious Adverse Outcomes: An Exploratory Analysis
  94. Combining High-Sensitivity Cardiac Troponin I and Cardiac Troponin T in the Early Diagnosis of Acute Myocardial Infarction
  95. Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department
  96. 1093Prognostic value of convalescent high-sensitivity troponin I concentrations following acute coronary syndrome
  97. Response to: “Letter to the Editor for ‘Low Versus Standard Urine Output Targets in Patients Undergoing Major Abdominal Surgery’”
  98. Development of a digital clinical pathway for emergency medicine: Lessons from usability testing and implementation failure
  99. Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study
  100. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease
  101. Acute Kidney Injury and mortality prognosis in Acute Coronary Syndrome patients: A meta‐analysis
  102. ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome)
  103. The Investigation and Treatment of Women who Present with Acute Chest Pain, Varies Little Compared with Men when Stratified by Risk
  104. Measured Implementation of an Accelerated Chest Pain Diagnostic Pathway in Primary Care
  105. Modification of the Thrombolysis in Myocardial Infarction risk score for patients presenting with chest pain to the emergency department
  106. A Risk Assessment Score and Initial High-sensitivity Troponin Combine to Identify Low Risk of Acute Myocardial Infarction in the Emergency Department
  107. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome
  108. Assessment of the 2016 National Institute for Health and Care Excellence high-sensitivity troponin rule-out strategy
  109. Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury
  110. The small number problem in diagnostic algorithms and why we need to bootstrap
  111. Direct Comparison of 2 Rule-Out Strategies for Acute Myocardial Infarction: 2-h Accelerated Diagnostic Protocol vs 2-h Algorithm
  112. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection
  113. Low Versus Standard Urine Output Targets in Patients Undergoing Major Abdominal Surgery
  114. Response by Than et al to Letter Regarding Article, “Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction”
  115. Plasma Neutrophil Gelatinase‐Associated Lipocalin diagnosed acute kidney injury in patients with systemic inflammatory disease and sepsis
  116. Nephrotoxicity-induced proteinuria increases biomarker diagnostic thresholds in acute kidney injury
  117. Validating the Manchester Acute Coronary Syndromes (MACS) and Troponin-only Manchester Acute Coronary Syndromes (T-MACS) rules for the prediction of acute myocardial infarction in patients presenting to the emergency department with chest pain
  118. Acute kidney injury—an overview of diagnostic methods and clinical management
  119. Neutrophil gelatinase-associated lipocalin (NGAL) fails as an early predictor of contrast induced nephropathy in chronic kidney disease (ANTI-CI-AKI study)
  120. National audit of the quality of pain relief provided in emergency departments in Aotearoa, New Zealand: The PRiZED 1 Study
  121. Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy
  122. Comparison of Five Accelerated Diagnostic Protocols for Stratification of Patients Presenting with Acute Chest Pain
  123. Measured Implementation of an Accelerated Chest Pain Diagnostic Pathway in Primary Care
  124. Immediate Rule-Out of Acute Myocardial Infarction Using Electrocardiogram and Baseline High-Sensitivity Troponin I
  125. Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction
  126. Use of a least absolute shrinkage and selection operator (LASSO) model to selected ion flow tube mass spectrometry (SIFT-MS) analysis of exhaled breath to predict the efficacy of dialysis: a pilot study
  127. Mechanism-specific injury biomarkers predict nephrotoxicity early following glyphosate surfactant herbicide (GPSH) poisoning
  128. Heart Fatty Acid Binding Protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction
  129. Bench to bedside: the next steps for biomarkers in acute kidney injury
  130. External validation of the emergency department assessment of chest pain score accelerated diagnostic pathway (EDACS-ADP)
  131. Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice
  132. Evaluation of High-Sensitivity Cardiac Troponin I Levels in Patients With Suspected Acute Coronary Syndrome
  133. Validation of NICE diagnostic guidance for rule out of myocardial infarction using high-sensitivity troponin tests
  134. The diagnostic ability of procalcitonin and interleukin-6 to differentiate infectious from noninfectious systemic inflammatory response syndrome and to predict mortality
  135. Impact of High-Sensitivity Troponin I Testing with Sex-Specific Cutoffs on the Diagnosis of Acute Myocardial Infarction
  136. A Clinical Decision Rule to Identify Emergency Department Patients at Low Risk for Acute Coronary Syndrome Who Do Not Need Objective Coronary Artery Disease Testing: The No Objective Testing Rule
  137. Validation of presentation and 3 h high-sensitivity troponin to rule-in and rule-out acute myocardial infarction
  138. Timely Diagnosis of Acute Kidney Injury Using Kinetic eGFR and the Creatinine Excretion to Production Ratio, E/eG - Creatinine Can Be Useful!
  139. Two-Hour Algorithm for Triage toward Rule-Out and Rule-In of Acute Myocardial Infarction by Use of High-Sensitivity Cardiac Troponin I
  140. The addition of ultrasound to other parameters to predict end state renal disease
  141. Time to presentation and 12-month health outcomes in patients presenting to the emergency department with symptoms of possible acute coronary syndrome
  142. Sex-specific versus overall cut points for a high sensitivity troponin I assay in predicting 1-year outcomes in emergency patients presenting with chest pain
  143. Best Albuminuria Measurement to Predict Cardiovascular and Renal Events
  144. Simplification of a scoring system maintained overall accuracy but decreased the proportion classified as low risk
  145. The utility of presentation and 4-hour high sensitivity troponin I to rule-out acute myocardial infarction in the emergency department
  146. The incremental value of stress testing in patients with acute chest pain beyond serial cardiac troponin testing
  147. Kidney damage biomarkers detect acute kidney injury but only functional markers predict mortality after paraquat ingestion
  148. Evaluation of biomarkers of cell cycle arrest and inflammation in prediction of dialysis or recovery after kidney transplantation
  149. Beware the dog that didn't bark: a tale of creatinine in acute kidney injury
  150. Perioperative change in creatinine following cardiac surgery with cardiopulmonary bypass is useful in predicting acute kidney injury: a single-centre retrospective cohort study
  151. Kinetic Estimation of GFR Improves Prediction of Dialysis and Recovery after Kidney Transplantation
  152. FP251THE PROGNOSTIC VALUE OF "ESTIMATED ALBUMIN EXCRETION RATE" (EAER) VERSUS URINE ALBUMIN/CREATININE RATIO (ACR) FOR PREDICTING ADVERSE CARDIOVASCULAR OUTCOME AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE G2-G4
  153. SP359PROGNOSTIC VALUE OF THE ,,ESTIMATED ALBUMIN EXCRETION RATE” TO PREDICT RENAL EVENTS IN CHRONIC KIDNEY DISEASE
  154. Two-hour diagnostic algorithms for early assessment of patients with acute chest pain — Implications of lowering the cardiac troponin I cut-off to the 97.5th percentile
  155. Comparison of the Performance of 2 GFR Estimating Equations Using Creatinine and Cystatin C to Predict Adverse Outcomes in Elderly Individuals
  156. Combining presentation high-sensitivity cardiac troponin I and glucose measurements to rule-out an acute myocardial infarction in patients presenting to emergency department with chest pain
  157. Acute Kidney Injury and Prognosis After Cardiopulmonary Bypass: A Meta-analysis of Cohort Studies
  158. Clusterin in Kidney Transplantation
  159. The clinical utility window for acute kidney injury biomarkers in the critically ill
  160. Acute kidney injury: Cell cycle arrest biomarkers win race for AKI diagnosis
  161. Acute Kidney Injury Urinary Biomarker Time-Courses
  162. Acute kidney injury: Late-onset acute kidney injury—subacute or more of the same?
  163. A Simple Method to Detect Recovery of Glomerular Filtration Rate following Acute Kidney Injury
  164. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation incorporating both cystatin C and creatinine best predicts individual risk: a cohort study in 444 patients with chronic kidney disease
  165. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment?
  166. Creatinine reduction ratio (CCR) is useful for excluding AKI after cardiac surgery: a preliminary retrospective study
  167. High-dose intravenous epoetin does not increase blood pressure in critically ill patients with acute kidney injury
  168. Linking Injury to Outcome in Acute Kidney Injury: A Matter of Sensitivity
  169. The Clinical Utility of Plasma Neutrophil Gelatinase-Associated Lipocalin in Acute Kidney Injury
  170. The urine output definition of acute kidney injury is too liberal
  171. Combining creatinine and volume kinetics identifies missed cases of acute kidney injury following cardiac arrest
  172. Explaining new methods to assess the added value of a biomarker
  173. Some biomarkers of acute kidney injury are increased in pre-renal acute injury
  174. Acute kidney injury clinical trial design: old problems, new strategies
  175. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients
  176. Challenges facing early detection of acute kidney injury in the critically ill
  177. Test Characteristics of Urinary Biomarkers Depend on Quantitation Method in Acute Kidney Injury
  178. Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI)
  179. Was It the Nephrologists or the Fluid?
  180. Albuminuria increases cystatin C excretion: implications for urinary biomarkers
  181. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function
  182. New considerations in the design of clinical trials of acute kidney injury
  183. Baseline creatinine: where to from here?
  184. Survivor Bias in Early- vs Late-Start Hemodialysis Studies
  185. Predictor of Early Diagnosis, Diagnosis, or Progression of Acute Kidney Injury
  186. Breath ammonia and trimethylamine allow real-time monitoring of haemodialysis efficacy
  187. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial)
  188. Back-Calculating Baseline Creatinine with MDRD Misclassifies Acute Kidney Injury in the Intensive Care Unit
  189. Urinary Soluble HLA-DR Is a Potential Biomarker for Acute Renal Transplant Rejection
  190. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit
  191. Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit
  192. New and better biomarkers of acute kidney injury
  193. Secondary prevention of acute kidney injury
  194. Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI)
  195. Evaluation of Trial Outcomes in Acute Kidney Injury by Creatinine Modeling
  196. GFR shot by RIFLE: errors in staging acute kidney injury
  197. RIFLE and AKIN - maintain the momentum and the GFR!
  198. Plagiarism
  199. In vitrodouble-integrating-sphere optical properties of tissues between 630 and 1064 nm
  200. Laser Treatment of Port Wine Stains
  201. Ultrastructural alterations in heated canine myocardium
  202. Vessel hyalinization phenomenon in the laser treatment of tuberous hemangiomas and port wine stains
  203. Wavelengths for laser treatment of port wine stains and telangiectasia
  204. Port-wine stain treatment is wavelength independent in the range 488–620 nm using 200-ms pulses
  205. Continuous measurement of the heat‐induced changes in the optical properties (at 1,064 nm) of rat liver
  206. Defining purpura
  207. Modeling the effect of wavelength on the pulsed dye laser treatment of port wine stains
  208. Changes in the optical properties (at 6328 nm) of slowly heated myocardium
  209. Double-integrating-sphere system for measuring the optical properties of tissue
  210. A SIMPLE METHOD TO AVOID DEPRESSED SCARRING IN LASER TREATMENT OF ELEVATED LESIONS
  211. Modeling the color perception of port wine stains and its relation to the depth of laser coagulated blood vessels
  212. Optical properties of rat liver and tumor at 633 nm and 1064 nm: Photofrin enhances scattering
  213. Monoline argon laser (514 nm) treatment of benign pigmented lesions with long pulse lengths
  214. Optical property changes as a result of protein denature in albumen and yolk
  215. Two integrating spheres with an intervening scattering sample
  216. The objective reporting of laser treatment of port wine stains
  217. A computer controlled scanner for the laser treatment of vascular lesions and hyperpigmentation
  218. On the scientific reporting of laser surgery
  219. Copper vapour laser treatment of port-wine stains and other vascular malformations
  220. Copper vapour laser treatment of port wine stains: a patient questionnaire
  221. Computed temperature distributions around ectatic capillaries exposed to yellow (578 nm) laser light